Gland Pharma shares rose sharply after Q1FY27 profit rose 47% and revenue grew 20% year-on-year. While strong margins and CDMO growth prompted Elara Securities to raise its earnings estimates, the brokerage downgraded the stock to ‘Accumulate’ from ‘Buy’ after its 40% three-month rally, citing limited near-term upside.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.